- Trials with a EudraCT protocol (109)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
109 result(s) found for: Aripiprazole.
Displaying page 1 of 6.
EudraCT Number: 2022-001582-12 | Sponsor Protocol Number: 4 | Start Date*: 2023-03-01 |
Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red (CIBER) | ||
Full Title: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. | ||
Medical condition: First episode SZ-spectrum individuals | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018860-17 | Sponsor Protocol Number: 31-08-257 | Start Date*: 2011-04-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) EE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001181-41 | Sponsor Protocol Number: CN138-125 | Start Date*: 2005-01-10 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices | ||
Medical condition: Schizophrenia or schizoaffective disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SK (Completed) CZ (Completed) HU (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002699-83 | Sponsor Protocol Number: 31-08-248 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FI (Completed) HU (Completed) AT (Completed) EE (Completed) DK (Prematurely Ended) FR (Completed) GB (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002676-10 | Sponsor Protocol Number: 31-07-247 | Start Date*: 2008-12-02 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) EE (Completed) HU (Completed) AT (Completed) FR (Completed) BG (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000174-11 | Sponsor Protocol Number: CN138603 | Start Date*: 2017-04-07 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | ||
Full Title: Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Subjects with Irritability Associated with Autistic Disorder | ||
Medical condition: Irritability in Autism Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-018858-12 | Sponsor Protocol Number: 31-08-256 | Start Date*: 2010-12-15 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder. | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) SK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018859-97 | Sponsor Protocol Number: 31-08-263 | Start Date*: 2010-10-04 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder. | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Prematurely Ended) HU (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000472-40 | Sponsor Protocol Number: CN138-169 | Start Date*: 2005-08-10 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy w... | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018796-21 | Sponsor Protocol Number: 31-08-255 | Start Date*: 2010-11-02 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder. | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005111-40 | Sponsor Protocol Number: CN138-178 | Start Date*: 2017-04-07 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | ||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Flexible- Dosed Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder | ||
Medical condition: Autistic Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000175-86 | Sponsor Protocol Number: CN138-180 | Start Date*: 2017-04-07 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, | ||
Full Title: A 52-Week, Open-label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder | ||
Medical condition: Autistic disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-005959-42 | Sponsor Protocol Number: CN138-502 | Start Date*: 2008-06-18 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Pat... | |||||||||||||
Medical condition: Bipolar I Mania (manic or mixed episode) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002270-48 | Sponsor Protocol Number: 31-14-204 | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’s Disorder | |||||||||||||
Medical condition: Tourette’s Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002675-27 | Sponsor Protocol Number: 31-07-246 | Start Date*: 2009-05-11 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003488-23 | Sponsor Protocol Number: 31-12-293 | Start Date*: 2013-01-30 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder | |||||||||||||
Medical condition: Tics associated with Tourette’s Disorder in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Prematurely Ended) BE (Completed) SE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) DE (Prematurely Ended) NL (Not Authorised) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000903-17 | Sponsor Protocol Number: CN138-166 | Start Date*: 2005-02-23 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003489-42 | Sponsor Protocol Number: 31-12-294 | Start Date*: 2013-03-12 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder | |||||||||||||
Medical condition: Tics associated with Tourette’s Disorder in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Ongoing) GB (Completed) ES (Prematurely Ended) IT (Completed) DE (Ongoing) SE (Completed) NL (Ongoing) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001809-25 | Sponsor Protocol Number: CN138-170 | Start Date*: 2005-12-23 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia. Revised Protocol 02... | ||
Medical condition: patients with schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) CZ (Completed) SE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020987-39 | Sponsor Protocol Number: 31-09-266 | Start Date*: 2012-10-15 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Long-Term Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Pati... | |||||||||||||
Medical condition: Schizophrenia in Adolescent Patients | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.